VieCure Raises $25 Million for Clinical Decision Support Platform

VieCure, a real-time clinical decision support system, announced the closing of its $25 million Series A growth equity investment round, led by Northpond Ventures.

An undisclosed investor also contributed to the round.

VieCure will use the new funding to accelerate its next-generation clinical decision support solution and sales and business development efforts.

VieCure offers a cloud-based artificial intelligence (AI)-enabled real-time clinical decision support system. According to the company, the system combines the latest in evidence and clinical trials with patient data to assist surgical oncologists, medical oncologists, radiation oncologists, hematologists, and clinical trial investigators in generating personalized treatment plans and managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care.

As part of the investment, Andrea Jackson, Director for Northpond Ventures, will join the new VieCure Board of Directors.

Jackson said: “The VieCure platform is an ideal operating solution for oncologists, nurses, pharmacists, and clinical trial professionals, given it is designed for the precision oncology era and supports clinical decision making at point-of-care. The precision oncology paradigm shift is underway, and the amount of data that clinicians are being expected to digest, consider, and action is often beyond the human condition.”

“The VieCure platform ingests these data discretely, inferences these data against the latest clinical evidence and trial protocols, and generates optimal treatment plan considerations for action while the patient is in the exam room. We are excited to be an investor in and collaborator with VieCure. I’m looking forward to working with the leadership team and new Board to advance their mission to improve outcomes for people with cancer,” Jackson added.

The company works with cancer centers and health systems in the United States, Bahamas, and Antigua and has strategic alliances with pharmaceutical, molecular diagnostic, and laboratory companies.

Clinical decision support companies raised $661 million in 2020, according to Mercom’s Q1 2021 Digital Health Funding and M&A Report.